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Objectives. The purpose of this study to determine whether use
of cardiac medications reflects evidence-based recommendations
for patients with non–ST elevation acute coronary syndromes.
Background. Agency for Health Care Policy and Research
practice guidelines for unstable angina recommend the use of
cardiac medications based on evidence from randomized trials. It
is unknown whether practitioners in the U.S., Canada and Europe
follow these recommendations in patients with non–ST elevation
acute coronary syndromes.
Methods. We studied 7,743 patients with non–ST elevation
acute coronary syndromes enrolled in the international Global
Use of Strategies to Open Occluded Arteries in Acute Coronary
Syndromes trial. The use of aspirin, beta-adrenergic blocking
agents, angiotensin-converting enzyme inhibitors and calcium
channel blocking agents was determined at discharge for all
patients and “ideal” patients (those with indications and no
contraindications). Using published estimates of relative mortal-
ity reductions with these drugs, we calculated the lives that could
have been saved at 1 year if discharge medication use had better
matched guideline recommendations.
Results. Overall, guideline adherence at discharge in “ideal”
patients was 85.6% for aspirin, 59.1% for beta-blockers and 51.7%
for angiotensin-converting enzyme inhibitors. Calcium channel
blockers were given to 26.7% of patients with a contraindication to
these drugs. These rates were similar across locations of enroll-
ment. Women and older patients less often received aspirin when
“ideal,” and younger patients more often received calcium chan-
nel blockers when they were contraindicated. If medication use
had been more evidence-based, 1-year mortality might have been
reduced by a relative 22%.
Conclusions. There is significant room for improvement in the
use of recommended drugs in patients with non–ST elevation
acute coronary syndromes. Medication use that more closely follows
recommendations could reduce mortality in this population.
(J Am Coll Cardiol 1998;32:2023–30)
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“Unstable angina” describes a broad spectrum of non–ST
elevation acute coronary syndromes, including crescendo an-
gina, angina at rest and non–Q wave myocardial infarction.
Across this range of clinical syndromes, unstable angina is a
frequent cause of morbidity and has been estimated to have a
1-year mortality as high as 12%, most of this risk occurring
within the first months after hospital discharge (1–3). Random-
ized trials have provided clear evidence that certain medica-
tions can reduce recurrent ischemic events and improve sur-
vival in patients with non–ST elevation acute coronary
syndromes. The Agency for Health Care Policy and Research
(AHCPR) and the National Heart, Lung, and Blood Institute
Clinical Practice Guidelines for the Treatment of Unstable An-
gina summarize this knowledge and recommend treatments
shown to be beneficial in clinical trials, in an attempt to
influence practice patterns and improve outcomes (1). Pre-
scribing patterns that fall short of guideline recommendations
may adversely affect the survival of patients with acute coro-
nary syndromes.
Our analysis describes the use of guideline-recommended
discharge medications in patients with non–ST elevation acute
coronary syndromes enrolled in the international Global Use
of Strategies to Open Occluded Arteries in Acute Coronary
Syndromes (GUSTO-IIb) trial. We investigated the use of four
drugs (aspirin, beta-adrenergic blocking agents, angiotensin-
converting enzyme inhibitors and calcium channel blocking
agents) overall and in patients with indications but no contra-
indications to each therapy. We examined their use by place of
enrollment and by predictors of appropriate care. Using esti-
mates from the literature for baseline mortality in this popu-
lation, we calculated the reduction in mortality that could have
been achieved with a more evidence-based approach to the use
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of these drugs in patients presenting with unstable angina.
Although medical regimens must continue to be tailored to the
individual circumstances of the patient, our study identifies
populations who may benefit from each therapy, enabling us to
quantify the potential impact of closer guideline adherence.
Methods
Study population. The GUSTO-IIb trial has been de-
scribed (4). Briefly, 12,142 patients with acute coronary syn-
dromes were enrolled at 373 hospitals in 13 countries between
May 1994 and October 1995. Patients were eligible for enroll-
ment if they had chest pain within the previous 12 h associated
with either transient or persistent electrocardiographic
changes. The trial population included 4,131 patients with
ST–segment elevation myocardial infarction and 8,011 with
non–ST elevation acute coronary syndromes (unstable angina
or non–Q wave myocardial infarction). Patients were random-
ized to receive 72 h of intravenous heparin or hirudin therapy
in addition to standard treatment and were followed for a
primary end point of death or myocardial (re)infarction at 30
days. Our analysis included the 7,743 patients with non–ST
elevation acute coronary syndromes enrolled in GUSTO-IIb
who survived to hospital discharge: 2,183 from the U.S., 892
from Canada and 4,668 from Europe.
Study design. This observational analysis investigated the
use of aspirin, beta-blockers, angiotensin-converting enzyme
inhibitors and calcium channel blockers in selected patients at
discharge. Inclusion and exclusion criteria for each medication
were derived from the Clinical Practice Guidelines for Unstable
Angina, the American Heart Association/American College of
Cardiology Practice Guidelines for Acute Myocardial Infarc-
tion and from established, validated quality indicators of
medication use (1,5,6). These criteria were selected to exclude
patients from the “ideal” category when clinicians might have
disagreed about the appropriateness of the therapy, and may
still include patients for whom therapy remains controversial.
We screened the baseline characteristics and in-hospital com-
plications available on the case report form for these criteria.
The number of patients in our population meeting at least one
inclusion or exclusion criterion for each medication, as well as
the percentage of those patients qualifying by each criterion,
are shown in the Appendix. The construction of the “ideal”
patient, different for each medication, is also shown in the
Appendix. First, potential patients were defined as those with
inclusion criteria for the use of aspirin, beta-blockers,
angiotensin-converting enzyme inhibitors or calcium channel
blockers. “Ideal” patients were then obtained by removing
patients with exclusion criteria from the population of poten-
tial patients, leaving only those who met inclusion criteria for
use without meeting any exclusion criterion. For example,
patients were considered “ideal” for angiotensin-converting
enzyme inhibitor use if they had an ejection fraction ,40% or
in-hospital congestive heart failure but did not have chronic
renal insufficiency, a creatinine level .177 mmol/L (.2.0 mg/dL)
or an ejection fraction .40%. For aspirin, beta-blockers and
angiotensin-converting enzyme inhibitors, we looked at use in
patients for whom they have been proven useful; for calcium
channel blockers, we looked at use in patients for whom they
have been shown to be hazardous.
Medication use. Medication use was recorded on the case
report form both at randomization and at discharge. Although
aspirin use was recommended in the protocol, the use of all
other drugs at discharge was left to the discretion of the
primary physician. Calcium channel blockers were divided into
two categories on the case report form: nifedipine, diltiazem,
or verapamil; or felodipine or amlodipine. We included only
those in the former category in our analysis, as more evidence
exists supporting their potential hazard in our population
(7–13). Based on a random sample review of 10% of all case
report form variables, there was .98% agreement between
discharge medication information found on the case report
form and that found in the corresponding medical records.
Data analysis. Baseline characteristics of patients and en-
rolling hospitals were expressed as percentages. Medication
use at discharge in all patients, potential patients and “ideal”
candidates was expressed as a percentage of the overall
population. Medication use was also determined for “ideal”
patients in the U.S., Canada and Europe. We tested for
significant differences in medication use by geographic region
using chi-square statistics. Odd ratios and 95% confidence
intervals (CIs) for the likelihood of an “ideal” patient receiving
a drug at discharge were determined by gender, age category
and previous hypertension or diabetes status.
Mortality estimates. One-year mortality for unstable an-
gina patients was estimated at 12%, and mortality for unstable
angina patients with reduced left ventricular function (ejection
fraction ,40% or congestive heart failure) was estimated at
21% (1–3,14,15). From these estimates, the expected number
of deaths in 1,000 patients at 1 year is 120 for unstable angina
patients overall and 210 for unstable angina patients with
reduced left ventricular function. From randomized trial data,
we know that aspirin reduces the incidence of reinfarction and
mortality at 1 year by about 50% in patients with unstable
angina (1,16,17), and beta-blockers afford a relative reduction
in 1-year mortality in this population of about 21% (18–22).
Angiotensin-converting enzyme inhibitors reduce mortality in
patients with reduced left ventricular function by about 23%
(14,15,23,24). The use of calcium channel blockers in patients
with unstable angina has been associated with a 23% excess
mortality for those with ischemic disease and poor left ventric-
ular function (7–12). We then estimated the lives that could
have been saved with 100% guideline adherence, using esti-
Abbreviations and Acronyms
AHCPR 5 Agency for Health Care Policy and Research
CI 5 confidence interval
GUSTO-IIb 5 Global Use of Strategies to Open Occluded
Arteries in Acute Coronary Syndromes
TIMI 5 Thrombolysis in Myocardial Infarction trial
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mates of the relative mortality reduction afforded by each
medication applied to the estimated mortality in the popula-
tion treated (120 potential lives saved/1,000 patients treated
for aspirin and beta-blockers and 210 potential lives saved/
1,000 patients treated for the use of angiotensin-converting
enzyme inhibitors and the avoidance of calcium channel
blockers). We then adjusted the potential lives saved for the
current rate of use of each drug in our population to determine
the actual lives saved. The additional lives that would have
been saved (if medication use followed guideline recommen-
dations) reflected the difference between the potential lives
saved and the actual lives saved with the current rate of use.
The actual 1-year mortality in our population (6.8%; 641/
7,743) was used to calculate the mortality reduction with ideal
use by subtracting the calculated additional lives saved from
actual deaths. This mortality reduction along with 95% CI is
shown.
Results
Clinical Characteristics
The baseline characteristics of the 7,743 patients with
non–ST elevation acute coronary syndromes included in our
analysis are shown in Table 1, as are the in-hospital complica-
tions and angiographic data. This population had a high
incidence of previous coronary artery disease; 76% had prior
angina, 31% had prior infarction and 12% had prior bypass
surgery. Of this population without ST segment elevation at
presentation, 41.6% later were classified as having had an
enrollment myocardial infarction. Of the 4,392 who underwent
angiography during hospitalization, only 4.4% were found to
have no coronary artery disease (,25% stenosis in any coro-
nary vessel), and 62% were found to have two- or three-vessel
disease ($50% stenosis).
Using the American Hospital Association files from 1994,
we compared demographics and certifications of the 181 U.S.
hospitals participating in GUSTO-IIb with the 5,123 other U.S.
hospitals of the same service code. Study hospitals were larger
and more likely to be accredited by the Joint Commission on
Accreditation of Health Care Organizations, be affiliated with
medical schools, have Accreditation Council for Graduate
Medical Education training programs and have cardiac cathe-
terization and surgery facilities than the average U.S. hospital
of similar service type (Table 2).
Overall use of discharge medications. Overall use of dis-
charge medications is shown in Table 3. Use is also shown for
Table 1. Patient Clinical Characteristics
Percentage of Patients
(n 5 7,743)
Medical history
Prior angina 76.2
Prior myocardial infarction 31.3
Prior bypass surgery 11.9
Prior congestive heart failure 6.6
Diabetes mellitus 18.4
Hypertension 47.8
Hypercholesterolemia 40.9
Chronic obstructive pulmonary disease 2.8
Renal insufficiency 1.4
Laboratory values
Creatinine .177 mmol/L (2.0 mg/dL) 1.4
Platelets ,100,000/mm3 1.0
In-hospital events
Enrolling myocardial infarction 41.6
Congestive heart failure 2.7
Atrioventricular block 1.4
Pulmonary edema 3.3
Major bleeding 7.0
Bypass surgery 13.3
Angioplasty 20.0
Catheterization data (n 5 4,392)
No coronary disease* 4.4†
Insignificant coronary disease 11.6†
1-vessel disease 26.4†
2-vessel disease 28.3†
3-vessel disease 33.7†
Ejection fraction ,40% 7.7
*Less than 25% stenosis in any coronary artery. †Percentage of those who
underwent cardiac catheterization.
Table 2. Comparison of U.S. Hospitals Participating in GUSTO-IIb
and Other U.S. Hospitals
GUSTO-IIb Hospitals
(n 5 181)
Other Hospitals
(n 5 5,123)
Number of beds
, 100 2.2 (4) 45.5 (2323)
101 to 250 25.4 (46) 32.4 (1658)
251 to 400 27.6 (50) 13.1 (667)
. 400 44.8 (81) 9.0 (462)
JCAHO accreditation 98.3 76.8
ACGME-accredited residency 56.9 17.8
Medical school affiliation 56.9 19.0
Council of Teaching Hospitals
member
28.2 5.9
Catheterization laboratory 95.7 44.1
Open-heart surgery facilities 69.9 28.1
Data presented are percentages (number) in each category. ACGME 5
Accreditation Council for Graduate Medical Education; JCAHO 5 Joint
Commission on Accreditation of Health Care Organizations.
Table 3. Discharge Medication Use in the Overall Population and
Selected Subgroups
Aspirin Beta-Blockers
ACE
Inhibitors
Calcium Channel
Blockers*
Overall patients (n 5 7,743) (n 5 7,743) (n 5 7,743) (n 5 7,743)
Use 83.2 55.0 22.5 41.6
Potential patients (n 5 7,743) (n 5 7,743) (n 5 513) (n 5 513)
Use 83.2 55.0 49.7 25.0
“Ideal” patients (n 5 6,175) (n 5 6,467) (n 5 433) (n 5 393)
Use 85.6 59.1 51.7 26.7
*Use of calcium blockers overall and in those for whom use was contrain-
dicated. Data presented are percentages of patients. ACE 5 angiotensin-
converting enzyme.
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potential and “ideal” patients for each drug. For aspirin and
beta blockers, overall use and potential use are identical,
because all patients were considered potential patients for
these therapies. The use of aspirin in “ideal” patients was only
slightly higher than its use in all patients (85.6% vs. 83.2%).
Although the use of beta-blockers in “ideal” patients was
greater than in potential patients, still only 59.1% of “ideal”
patients received this drug at discharge. The use of
angiotensin-converting enzyme inhibitors was more than dou-
bled in “ideal” patients compared with the overall population
(51.7% vs. 22.5%). Likewise, the use of calcium channel
blockers was nearly halved in patients who were selected as
“ideal” for avoidance of this medication compared with the
overall population (26.7% vs. 41.6%).
International use of discharge medications. The ideal use
by international region of enrollment was similar to the ideal
use in the overall population (Table 4). Canada differed
significantly from the U.S. in its higher use of beta-blockers in
“ideal” patients but not in the use of other medications.
Europe differed significantly from the U.S. in the higher use of
aspirin in “ideal” patients but not in the use of other medica-
tions. The use of angiotensin-converting enzyme inhibitors and
the nonuse of calcium channel blockers in “ideal” patients did
not differ significantly among regions.
Likelihood ratios for receiving medications at discharge.
For each group of “ideal” patients, we compared the likelihood
of receiving a drug at discharge by certain baseline character-
istics (Table 5). Women and older patients in the “ideal”
category were less likely to receive aspirin at discharge. For
example, men were 50% more likely to receive aspirin at
hospital discharge than women, and patients younger than age
65 were 25% more likely to receive aspirin than those over age
75. Older patients were more likely to receive beta-blockers
when “ideal,” whereas younger patients were more likely to
receive calcium channel blockers even though they were
“ideal” for their avoidance. In addition, patients with hyper-
tension were more likely to receive beta-blockers, and diabet-
ics were more likely to receive calcium channel blockers, at
discharge.
Mortality reductions with evidence-based use of medica-
tions. If medication use in “ideal” patients increased from its
current rate to 100%, the number of additional lives that could
be saved per 1,000 patients treated is shown in the last column
of Table 6. We converted these numbers to the additional
number of lives saved in our population of ideal patients if all
ideal patients had been treated. The nine additional lives per
1,000 ideal patients treated that could be saved by increasing
the use of aspirin from 85.6% to 100% translate into 56
additional lives in our population of 6,175 patients who are
ideal for aspirin. Increased beta-blocker use could have re-
sulted in an additional 71 lives saved of 6,467 “ideal” patients
treated, and increased angiotensin-converting enzyme inhibi-
tor use could have saved an additional nine lives of 433 “ideal”
patients treated. The decreased use of calcium channel block-
ers could have saved an additional five lives of 393 “ideal”
patients with their nonuse. In total, 141 lives could have been
saved in our population of 7,743 patients, or 18 additional lives
saved per 1,000 treated, with guideline-recommended medica-
tion use. The actual 1-year mortality in our population after
hospital discharge was 8.3% (641 deaths); altering medication
use toward the ideal could have reduced the 1-year mortality
rate to 6.5% (500 deaths). This 6.5% mortality (95% CI 5.9%
Table 5. Odds Ratios with 95% Confidence Intervals for the Likelihood of “Ideal” Patients Receiving
Discharge Medication
Aspirin Beta-Blockers ACE Inhibitors
Calcium Channel
Blockers*
Men (vs. women) 1.49 (1.29, 1.72) 1.03 (0.93, 1.15) 0.92 (0.61, 1.40) 0.92 (0.56, 1.50)
Age 65 to 75 (vs. age , 65) 0.85 (0.73, 1.00) 1.12 (1.05, 1.32) 0.93 (0.61, 1.44) 0.77 (0.46, 1.29)
Age . 75 (vs. age , 65) 0.76 (0.62, 0.93) 1.33 (1.16, 1.52) 1.21 (0.74, 1.98) 0.55 (0.31, 0.97)
Hypertension (yes vs. no) 0.92 (0.80, 1.06) 1.21 (1.10, 1.34) 1.12 (0.77, 1.64) 1.43 (0.91, 2.24)
Diabetes (yes vs. no) 0.95 (0.79, 1.14) 0.89 (0.79, 1.02) 1.45 (0.96, 2.21) 1.82 (1.14, 2.92)
*Use of calcium channel blockers in those in whom use was contraindicated. ACE 5 angiotensin-converting enzyme.
Table 4. Discharge Medication Use in “Ideal” Patients by Enrollment Location
Medication
U.S. Canada Europe
Ideal Patients
(n)
Use
(%)
Ideal Patients
(n)
Use
(%)
Ideal Patients
(n)
Use
(%)
Aspirin 1514 83.9 741 86.4 3375 86.1*
Beta-blockers 1677 58.7 732 70.0† 4058 57.3
ACE inhibitors 207 54.6 59 49.2 167 49.1
Calcium channel blockers‡ 188 25.0 48 16.7 157 31.9
*p , 0.05 for use of aspirin at discharge compared with U.S. †p , 0.001 for use of beta-blockers at discharge
compared with U.S. ‡Use of calcium channel blockers in those in whom use was contraindicated. ACE 5 angiotensin-
converting enzyme.
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to 7.0%) translates into a relative reduction in mortality of
22% (95% CI 16% to 44%) with more evidence-based clinical
practices. If medication use improved only 75% toward guide-
line recommendations, it would result in 106 lives saved in our
population of 7,743 patients, yielding a 1-year mortality of
6.9% (535 deaths) and a relative risk reduction for mortality of
17%.
Discussion
This study describes medication use in a large, international
population of patients with non–ST elevation acute coronary
syndromes, and is unique in estimating the impact on mortality
that suboptimal adherence to guideline recommendations may
have in this population. We found that the use of cardiac
medications in patients with non–ST elevation acute coronary
syndromes falls short of guideline recommendations across
international practice, and that significant mortality reductions
may be achieved with a more evidence-based approach to the
use of aspirin, beta-blockers, angiotensin-converting enzyme
inhibitors and calcium channel blockers.
The purpose of our analysis was to determine the adher-
ence to these medical recommendations in general practice by
applying published guidelines in broad strokes to a large
population. Therefore, we used purposefully narrow criteria to
select “ideal” patients, and may have excluded some patients
from this category who might have benefited from these
therapies. For example, we excluded patients with reduced left
ventricular function from consideration for beta-blockers, al-
though recent studies have indicated the potential for mortality
reduction with these agents (25). In addition, we excluded
felodipine and amlodipine from our analysis of calcium chan-
nel blockers, as these agents have not been shown to be
hazardous and may be useful as adjunctive therapy in patients
with ischemic heart disease (13). With these caveats in mind,
our analysis provides a broad view of guideline-recommended
uses of each medication and does not specify the ideal medical
regimen for each patient.
Although guideline-recommended use of medications has
been well described in patients with acute myocardial infarc-
tion, less is known about their “ideal” use in an unstable angina
population. Although the heterogeneity in clinical presenta-
tion and acuity of an unstable angina population can make
applying uniform guidelines challenging, our population was
uniquely suited for this analysis due to a high degree of
coronary disease severity and acuity. For example, many had
prior cardiac diagnoses, 42% were diagnosed with an enroll-
ment infarction and 84% of those undergoing angiography had
significant coronary disease. A previous analysis of the unsta-
ble angina population in GUSTO-IIb has shown 97.6% of
these patients to be in the intermediate and high risk catego-
ries according to unstable angina guidelines (26). In addition to
the high risk and likelihood of coronary disease of our patients,
the GUSTO-IIb enrolling hospitals were high volume, cardio-
vascular referral centers from around the world. Based on
these patient and hospital characteristics, we expected a higher
than average adherence to guideline recommendations in our
population compared with general practice, even though we
have shown this adherence to be suboptimal.
The Thrombolysis in Myocardial Infarction trial (TIMI)-III
Registry Study Group recently reported medication use with-
out adjustment for indications and contraindications in a
similar population of patients with unstable angina and non–Q
wave myocardial infarction (27). The overall rates of use in
their U.S. population were 82.5% for aspirin, 39.5% for
beta-blockers and 54.3% for calcium channel blockers. Com-
paring the overall rates in their registry with those in our
analysis, we found a similar use of aspirin, a lower use of
calcium channel blockers and a higher use of beta-blockers.
Our study shows, however, that indications and contraindica-
tions do not explain the gap between actual and recommended
use of medications seen in large cardiovascular trial registries.
Compared with reports of the medication use in the acute
myocardial infarction and congestive heart failure populations,
we found similar patterns of underuse of guideline-recommended
medical therapies in our population (5,21,28,29). The 86% use
of aspirin in our unstable angina population compares favor-
ably with reported rates of aspirin use after ST elevation
myocardial infarction, which have ranged from 81% to 84%
(5,28,30). Since aspirin use was recommended in the protocol,
the rate of aspirin use in our population may be higher than
that found in general practice. Reports of in-hospital use of
beta-blockers after ST elevation myocardial infarction range
from 45% to 53% (5,22,28,30), compared with the 59% overall
use of beta-blockers in our analysis. The use of angiotensin-
converting enzyme inhibitors in patients admitted for manage-
Table 6. Estimated Lives Saved by Guideline-Recommended Use of Medications
Medication
Estimated Mortality
Reduction (Increase)*
Lives Saved (Lost)
per 1,000 Treated†
Current Use,
“Ideal” Patients
Lives Saved (Lost)
per 1,000 Treated,
Current Use
Additional Lives
Saved per 1,000
Treated, Ideal Use
Aspirin 50% 60 85.6% 51 9
Beta-blockers 21% 28 59.1% 17 11
ACE inhibitors 23% 48 51.7% 25 23
Calcium channel blockers (23) (48) 26.7% (13) 13
*References: aspirin (1,8,9), beta-blockers (10,13,14), angiotensin-converting enzyme (ACE) inhibitors (6,7,15,16), calcium channel blockers (17–23). †For aspirin
and beta-blockers, 1-year mortality estimated at 12% for all unstable angina patients. For ACE inhibitors and calcium channel blockers, 1-year mortality estimated at
21% for patients with a low ejection fraction.
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ment of heart failure was 47% in one study (29), and
angiotensin-converting enzyme inhibitor use in patients with
reduced left ventricular function after infarction has been
reported to be ,40% (31). We report a higher, 51% use in
patients admitted for unstable angina with a low ejection
fraction. There are no other reports with which to compare the
use of calcium channel blockers in patients for whom their use
is contraindicated. Overall, our findings in a large population
of patients with non–ST elevation acute coronary syndromes
are similar to those in registries of patients with ST elevation
acute myocardial infarction.
There were minimal differences in the use of discharge
medications internationally, with two exceptions. One was the
higher use of beta-blockers in Canada, also found in the
TIMI-III Registry (27), and the other was the higher use of
aspirin in Europe. Despite the slightly better rates in Canada
and Europe, use of medications consistently fell short of
recommendations regardless of place of enrollment. There-
fore, improvements in guideline-recommended use of medica-
tions are needed across international practice.
Interestingly, certain patient characteristics influenced the
likelihood of “ideal” patients receiving medications at dis-
charge. We found that gender and age influenced the likeli-
hood of receiving aspirin, with women and older patients being
less likely to receive aspirin at discharge. In addition, younger
patients and diabetics were both more likely to be given
calcium channel blockers and less likely to be given beta-
blockers. These differences may result from a perception that
certain groups are less likely to have coronary artery disease or
from concerns over side effect profiles of these agents in
certain patients. Awareness of these trends will help physicians
focus their efforts to improve guideline adherence toward
specific subgroups of patients in whom medications are now
underused.
Estimate of benefit. Observational reports suggest that
patients who are “ideal” for medications and actually receive
them have better survival than those who do not (28,32,33).
However, any nonrandomized comparison of survival by dis-
charge medication is obviously confounded by unknown fac-
tors in the selection of patients for treatment. Patients not
receiving therapy are likely to be at higher risk due to the
presence of contraindications and therefore may have a higher
mortality. In addition, since the absolute benefit of a treatment
depends on the inherent risk of the patient subgroup, the
absolute benefit may be even larger among this untreated
group of patients. Because of these factors, we elected to
predict mortality reductions using literature estimates of ben-
efit instead of comparing observed 6-month and 1-year mor-
tality for “ideal” patients within our population. In addition,
the literature estimates of baseline mortality are unaffected by
current rates of medication use in our population. By our
methods, we estimated that by increasing medication use to
100% of the ideal, 141 lives out of our population of 7,743
could have been saved at 1 year for a 22% mortality reduction.
This translates to 18 lives saved per 1,000 patients treated per
year in a more evidence-based clinical practice. Assuming
there are undetected but legitimate reasons for underuse of
beneficial therapies, we also calculated the mortality reduc-
tions for moving only 75% toward the goal of 100% ideal and
found that a 17% relative mortality reduction would still result.
This rivals and surpasses the mortality benefits seen with many
of the newer therapies for acute coronary syndromes. For
comparison, treatment with hirudin in the GUSTO-IIb trial
afforded a 9% relative risk reduction in death and myocardial
infarction at 30 days compared with heparin (4).
Study limitations. Our study has several limitations. First,
the AHCPR guidelines are published in the U.S., and non-U.S.
investigators may be less aware of their content. They do,
however, contain practice recommendations that are based on
the results of widely known international, randomized clinical
trials. Second, U.S. hospitals participating in GUSTO-IIb
differ in many service indicators from national averages in that
they are larger and more often academically affiliated, and they
provide more cardiovascular services. In addition, our non-
U.S. hospitals also represent the large, tertiary care referral
centers within their geographic regions. Therefore, practice
patterns in these hospitals may not accurately represent med-
ical practice in the community. Third, information that was
unavailable through the case report form may have played a
crucial role in the decision to prescribe or withhold a medica-
tion. Patient-reported aspirin intolerance may have resulted in
the use of antiplatelet agents other than aspirin. In addition,
limitations in blood pressure may have prevented the use of
more than one medication before discharge, although there
may have been several for which the patient was “ideal.” The
frequent use of calcium channel blockers in our population
may be due partly to a hesitance on the part of hospital
physicians to alter preexisting, presumably effective outpatient
medical regimens. In addition, we determined medication use
only at discharge. We did not account for drugs used earlier
during hospitalization that were discontinued for intolerance,
or those whose use was planned to begin after discharge. Due
to these limitations, we suspect that actual use may be closer to
appropriate than our numbers would suggest. We do not have
information on the dosages of prescribed drugs, and therefore
we do not know whether patients received the same dosages
proven to reduce mortality in clinical trials. Finally, our
literature-based prediction of mortality reduction was calcu-
lated by adding the individual effect of each medication, when
in practice, the combined medical regimen may affect clinical
outcome in a manner that is not purely additive.
Conclusions. There is significant room for improvement in
clinical practice by increasing the use of medications known to
improve outcomes in patients with non–ST elevation acute
coronary syndromes. Too often, patients who are “ideal” for
these therapies are discharged without them. This may be a
result of inattention to the medical regimen at discharge, to
lack of knowledge about guideline recommendations or to
physicians’ concern over adverse effects of these drugs in
certain subgroups. Although guidelines are not a mandate for
compliance with a medical regimen, if they were followed more
closely, significant mortality reductions could be expected in
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patients with unstable angina worldwide. Thus, as the medical
community develops new therapies for treatment of acute
coronary syndromes, physicians must remember to use the
basic medications proven over time to be of benefit in these
patients.
We would like to acknowledge the excellent editorial assistance of Ms. Patricia
Williams in the preparation of the manuscript.
Appendix: Selection Criteria for
“Ideal” Patients
Aspirin use at discharge:
● Inclusion criteria (n 5 7,743): All patients.
● Exclusion criteria (n 5 1,568): Discharged on warfarin (34%), major
bleeding (34%), platelet count ,100,000/mm3 (5%) or hemoglobin
,10 mg/dL (61%).
● “Ideal” patients (n 5 6,175) 5 potential patients (n 5 7,743) 2
excluded patients (n 5 1,568).
Beta-blocker use at discharge:
● Inclusion criteria (n 5 7,743): All.
● Exclusion criteria (n 5 1,276): No significant angiographic coronary
disease (29.5%), ejection fraction ,40% (26.5%), in-hospital con-
gestive heart failure (16.2%), pulmonary edema (20.1%), shock
(4.5%), second- or third-degree heart block (8.5%), chronic ob-
structive pulmonary disease (17.0%).
● “Ideal” patients (n 5 6,467) 5 potential patients (n 5 7,743) 2
excluded patients (n 5 1,276).
Angiotensin-converting enzyme inhibitor use, patients with reduced
ejection fraction at discharge:
● Inclusion criteria (n 5 513): Ejection fraction ,40% (66%), in-
hospital congestive heart failure (40%).
● Exclusion criteria (n 5 2,708): History of chronic renal insufficiency
(4%), creatinine .177 mmol/L (2.0 mg/dL, 4%), ejection fraction
.40% (95%).
● “Ideal” patients (n 5 433) 5 potential patients (n 5 513) 2
excluded patients (n 5 80).
No calcium-channel blocker use, patients with reduced ejection frac-
tion at discharge:
● Inclusion criteria (n 5 513): Discharged with ejection fraction
,40% (66%), in-hospital congestive heart failure (40%).
● Exclusion criteria (n 5 2,870): Ejection fraction .40% (90%), atrial
fibrillation (17%).
● “Ideal” patients (n 5 393) 5 potential patients (n 5 513) 2
excluded patients (n 5 120).
References
1. Braunwald E, Mark D, Jones R, et al. Unstable Angina: Diagnosis and
Management. Clinical Practice Guideline Number 10, Publication 94-0602.
Rockville, MD: Agency for Health Care Policy and Research, 1994.
2. Wilcox I, Freedman SB, McCredie RJ, Carter GS, Kelly DT, Harris PJ. Risk
of adverse outcome in patients admitted to the coronary care unit with
suspected unstable angina pectoris. Am J Cardiol 1989;64:845–8.
3. White LD, Lee TH, Cook EF, et al., and the Chest Pain Study Group.
Comparison of the natural history of new onset and exacerbated chronic
ischemic heart disease. J Am Coll Cardiol 1990;16:304–10.
4. The Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO-IIb) Investigators. A comparison of recombinant hirudin with
heparin for the treatment of acute coronary syndromes. N Engl J Med
1996;335:775–82.
5. Ellerbach EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare
patients with acute myocardial infarction. JAMA 1995;273:1509–14.
6. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction. J Am Coll Cardiol
1996;28:1328–428.
7. Muller JE, Turi ZG, Pearle DI, et al. Nifedipine and conventional therapy
for unstable angina pectoris: a randomized, double-blind comparison. Cir-
culation 1984;69:728–39.
8. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect
of diltiazem on mortality and reinfarction after myocardial infarction. N Engl
J Med 1988;319:385–92.
9. Poole-Wilson PA. Angiotensin-converting enzyme inhibitors and calcium
antagonists after acute myocardial infarction. Am J Cardiol 1995;75:4E–9E.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in
mortality in patients with coronary heart disease. Circulation 1995;92:1326–
31.
11. Held P, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial
infarction and unstable angina: an overview. Br Med J 1989;299:1187–92.
12. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S, the Adverse Experience
Committee and the Multicenter Diltiazem Postinfarction Research Group.
Diltiazem increases late-onset congestive heart failure in postinfarction
patients with early reduction in ejection fraction. Circulation 1991;83:52–60.
13. Packer M, O’Connor CM, Ghali JK, et al., for the Prospective Randomized
Amlodipine Survival Evaluation Study Group. Effect of amlodipine on
morbidity and mortality in severe chronic heart failure. N Engl J Med
1996;335:1107–14.
14. Garg R, Yusuf S. Overview of randomized trials of angiotensin converting
enzyme inhibitors on mortality and morbidity in patients with heart failure.
JAMA 1995;273:1450–6.
15. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality
and morbidity in patients with left ventricular dysfunction after myocardial
infarction: results of the Survival and Ventricular Enlargement trial. N Engl
J Med 1992;327:669–77.
16. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in
unstable angina: results of a Canadian multicenter trial. N Engl J Med
1985;313:1369–75.
17. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin
against acute myocardial infarction and death in men with unstable angina.
N Engl J Med 1983;309:396–403.
18. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug
therapy in acute myocardial infarction: an overview of results from random-
ized controlled trials. JAMA 1993;270:1589–95.
19. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and
after myocardial infarction: an overview of the randomized trials. Prog
Cardiovasc Dis 1985;27:335–71.
20. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical
trials in heart disease. I: Treatments following myocardial infarction. JAMA
1988;260:2088–93.
21. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM. B-Blocker therapy in acute
myocardial infarction: evidence for underutilization in the elderly. Am J Med
1992;93:605–10.
22. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists’ practices
compared with practice guidelines: use of beta-blockade after acute myocar-
dial infarction. J Am Coll Cardiol 1995;26:1432–6.
23. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in
severe congestive heart failure: results of the Cooperative North Scandina-
vian Enalapril Survival Study. N Engl J Med 1987;316:1429–35.
24. The SOLVD Investigators. Effect of enalapril on mortality and the devel-
opment of heart failure in asymptomatic patients with reduced left ventric-
ular ejection fractions. N Engl J Med 1992;327:685–91.
25. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality
in patients with heart failure: a meta-analysis of randomized clinical trials.
J Am Coll Cardiol 1997;30:27–34.
26. Alexander KP, Peterson ED, Hellkamp AS, Granger CB, Topol EJ, Califf
RM, for the GUSTO IIb Investigators. Early catheterization is standard
strategy in unstable angina/NQWMI: results from GUSTO-IIb (abstr). J Am
Coll Cardiol 1997;29:450A.
27. Anderson HV, Gibson RS, Stone PH, et al. for the TIMI-III Registry Study
Group. Management of unstable angina and non-Q wave acute myocardial
infarction in the United States and Canada (the TIMI-III Registry). Am J
Cardiol 1997;79:1441–6.
28. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national
2029JACC Vol. 32, No. 7 ALEXANDER ET AL.
December 1998:2023–30 MEDICAL THERAPY IN ACUTE CORONARY SYNDROMES
guidelines for drug treatment of suspected acute myocardial infarction:
evidence for undertreatment in women and the elderly. Arch Intern Med
1996;156:799–805.
29. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of
angiotensin converting enzyme inhibitor use in congestive heart failure in
two community hospitals. Am J Cardiol 1996;77:832–8.
30. Rogers WJ, Bowlby LJ, Chandra NC, et al. for the Participants in the
National Registry of Myocardial Infarction. Treatment of myocardial infarc-
tion in the United States (1990 to 1993): observations from the National
Registry of Myocardial Infarction. Circulation 1994;90:2103–14.
31. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of
appropriate use of angiotensin-converting enzyme inhibitors after acute
myocardial infarction in persons .65 years of age. Am J Cardiol
1997;79:581– 6.
32. Koenig W, Lowel H, Lewis M, Horman A. Long-term survival after
myocardial infarction: relationship with thrombolysis and discharge medica-
tion. Eur Heart 1996;17:1199–206.
33. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G,
Goldman L. Adverse outcomes of underuse of beta-blockers in elderly
survivors of acute myocardial infarction. JAMA 1997;277:115–21.
2030 ALEXANDER ET AL. JACC Vol. 32, No. 7
MEDICAL THERAPY IN ACUTE CORONARY SYNDROMES December 1998:2023–30
